Allergy Therapeutics PLC Grant of Awards under Long Term Incentive Plan (1161G)

TIDMAGY

RNS Number : 1161G

Allergy Therapeutics PLC

02 November 2018

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Grant of Awards under Long Term Incentive Plan

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at a nominal cost of 0.1 pence each on 1 November 2018 (the "Awards").

 
 Executive Director    Number of Conditional   Total conditional 
                        shares awarded          shares held under 
                                                LTIPs 
 Manuel Llobet         900,000                 3,490,000 
                      ----------------------  ------------------- 
 Nick Wykeman          450,000                 1,322,500 
                      ----------------------  ------------------- 
 

The Awards have been granted in accordance with the LTIP rules and vesting is conditional on the satisfaction of performance conditions in respect of earnings growth and share price growth.

In addition, Manuel Llobet holds share options in respect of 2,155,423 shares relating to a vested LTIP award.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Manuel Llobet 
                              Nicolas Wykeman 
     ---------------------  ------------------------------------------------ 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status        Manuel Llobet - Chief Executive Office and PDMR 
                              Nicolas Wykeman - Chief Financial Officer and 
                              PDMR 
     ---------------------  ------------------------------------------------ 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------------ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                   ALLERGY THERAPEUTICS PLC 
     ---------------------  ------------------------------------------------ 
 b)   LEI                    213800PQ7AHK7KGVOE23 
     ---------------------  ------------------------------------------------ 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ----------------------------------------------------------------------- 
 a)   Description            Conditional award of shares under the Company's 
       of the financial       Long Term Incentive Plan 
       instrument, 
       type of instrument 
     ---------------------  ------------------------------------------------ 
 b)   Identification         GB00B02LCQ05 
       code 
     ---------------------  ------------------------------------------------ 
 c)   Nature of the          Grant of Conditional Awards 
       transaction 
     ---------------------  ------------------------------------------------ 
 d)   Price(s) and             Price(s)    Volume(s) 
       volume(s)                GBP0.001    900,000 
                                GBP0.001    450,000 
     ---------------------  ------------------------------------------------ 
 e)   Aggregated 
       information 
 
 
       - Aggregated            N/A (Single transaction) 
       volume 
 
 
       - Price 
     ---------------------  ------------------------------------------------ 
 f)   Date of the            1 November 2018 
       transaction 
     ---------------------  ------------------------------------------------ 
 g)   Place of the           Outside a trading venue 
       transaction 
     ---------------------  ------------------------------------------------ 
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Nick Brown

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHDDBDBGBGBGIB

(END) Dow Jones Newswires

November 02, 2018 03:00 ET (07:00 GMT)